Synopsys (SNPS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

27.02.25 00:00 Uhr

Werte in diesem Artikel
Aktien

408,05 EUR -9,25 EUR -2,22%

Indizes

19.281,4 PKT -517,2 PKT -2,61%

17.323,0 PKT -481,0 PKT -2,70%

5.580,9 PKT -112,4 PKT -1,97%

For the quarter ended January 2025, Synopsys (SNPS) reported revenue of $1.46 billion, down 11.8% over the same period last year. EPS came in at $3.03, compared to $3.56 in the year-ago quarter.The reported revenue represents a surprise of +0.16% over the Zacks Consensus Estimate of $1.45 billion. With the consensus EPS estimate being $2.81, the EPS surprise was +7.83%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Synopsys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Maintenance and service: $258.95 million versus the four-analyst average estimate of $264.09 million. The reported number represents a year-over-year change of -12.8%. Revenue- Total products revenue: $1.20 billion versus the four-analyst average estimate of $1.19 billion. The reported number represents a year-over-year change of -11.5%. Revenue by segment- Design IP: $435.10 million compared to the $425.91 million average estimate based on three analysts. The reported number represents a change of -17.2% year over year. Revenue by segment- Design Automation: $1.02 billion versus $1.02 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.5% change. Revenue- Upfront products: $368.12 million compared to the $395.06 million average estimate based on three analysts. The reported number represents a change of -17.8% year over year. Revenue- Time-based products: $828.24 million versus the three-analyst average estimate of $783.55 million. The reported number represents a year-over-year change of -8.4%. View all Key Company Metrics for Synopsys here>>>Shares of Synopsys have returned -13% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Synopsys, Inc. (SNPS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Synopsys und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Synopsys

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Synopsys

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Synopsys Inc.

Wer­bung

Analysen zu Synopsys Inc.

DatumRatingAnalyst
22.08.2019Synopsys BuyNeedham & Company, LLC
03.04.2019Synopsys BuyNeedham & Company, LLC
28.03.2019Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyThe Benchmark Company
DatumRatingAnalyst
22.08.2019Synopsys BuyNeedham & Company, LLC
03.04.2019Synopsys BuyNeedham & Company, LLC
28.03.2019Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyThe Benchmark Company
DatumRatingAnalyst
09.09.2015Synopsys HoldThe Benchmark Company
04.12.2008Synopsys UpgradeCitigroup Corp.
02.02.2007Synopsys neutralDA Davidson
31.01.2007Update Synopsys Inc.: NeutralDA Davidson
30.11.2006Synopsys holdDeutsche Securities
DatumRatingAnalyst
21.08.2008Synopsys DowngradeCitigroup Corp.
24.06.2005Synopsys underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Synopsys Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen